BioNTech SE · NASDAQ:BNTX
BioNTech — Q3 2026 Earnings Presentation
27 slides from BioNTech's earnings presentation, Nov 3, 2026
Slide 1: Third Quarter 2026 Financial Results & Corporate Update
Third Quarter 2026 Financial Results & Corporate Update November 3, 2026 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, refe
Slide 3: Agenda and presenters
1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer 3
Slide 4: Progress Highlights
Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 1 4
Slide 5: Oncology Focus in 2026: Progress in Q3
ONCOLOGY FOCUS IN 2026 PROGRESS IN Q3 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Gotistobart clinical benefit validated in OS data presented at WCLC Combination Therapy Momentum Pumitamig1 + ADC combination to advance into registrational path Pumi
Slide 6: Building a Multi-Product Company Across Tumor Focus Areas by 2030+
Building a Multi-Product Company Across Tumor Focus Areas by 2030+ Targeting 17+ Late-Stage and Pivotal Trial Readouts Informing Multiple Launch Opportunities 6 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials Expected Data Readouts2 2026 2027 2028 2029 2030+ Lung 1L NSCLC 400K Pumitamig3 ROSE
Slide 7: Oncology Execution
Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 7
Slide 8: Tumor-type Focused Strategy to Address Oncology Unmet Needs
Tumor-type Focused Strategy to Address Significant Oncology Unmet Medical Needs 8 GastrointestinalBreastLung Genitourinary Gynecologic Additional Tumors Data presented at WCLC and ESMO validate clinical benefit of BioNTech’s product candidates across key tumor types
Slide 9: Unique Opportunity to Build a Diversified Lung Cancer Franchise
Elfetabart Drozuntecan3 Unique Opportunity to Build a Diversified Lung Cancer Franchise 9 Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio. Gotistobart2Pumitamig1 Bispecific antibody targeting PD-L1 and VEGF-A with next- gen IO backbone potential TME-selective regulatory T cell-depl
Slide 10: Broadening Lung Cancer Coverage to Maximize Pipeline Potential
NSCLC SCLC Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K 80K 35K Broadening BioNTech’s Lung Cancer Coverage to Maximize Pipeline Potential 10 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2
Slide 11: Gotistobart Phase 3 Data Show Nearly Doubled Median Overall Survival vs SoC
Gotistobart Phase 3 Data Show Nearly Doubled Median Overall Survival vs SoC 11 Gotistobart (n=45) Docetaxel (n=42) Median OS, mos. 10.0 HR 0.56 Partnered with: 1. OncoC4, 2. Data presented at WCLC 2026. Median OS was 18.5 months with gotistobart1 vs 10.0 months with docetaxel2 Gotistobart continues
Slide 12: Broadening Lung Cancer Coverage to Maximize Pipeline Potential
NSCLC SCLC Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K 80K 35K Broadening BioNTech’s Lung Cancer Coverage to Maximize Pipeline Potential 12 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2
Slide 13: Pumitamig + Elfetabart Drozuntecan Shows Early Antitumor Activity in SCLC
Pumitamig1 plus ADC elfe-D2 elicits 70.4% ORR in SCLC3 –100 –80 –60 –40 –20 0 20 40 60 Pe rc en ta ge c ha ng e fr om b as el in e (% ) Pumitamig + Elfetabart Drozuntecan Demonstrates Early Antitumor Activity Across SCLC Treatment Lines 13 ORR Overall (n=71) 70.4% 1L (n=13) 92.3% 2L (n=21) 76.2% 3L+
Slide 14: Pumitamig + ADC Combination Development Enters Pivotal Phase
Pumitamig + ADC Combination Development Enters Pivotal Phase 14 1. Phase 1/2 Data presented at ESMO BREAST 2026. Partnered with: 2. Bristol Myers Squibb; 3. DualityBio; 4. Phase 3 collaboration with Gilead. ROSETTA Breast-01: An ongoing Phase 3 trial updated to reflect the evolving 1L TNBC standard
Slide 15: mRNA Cancer Immunotherapy iNeST and FixVac Portfolio Development Focus
mRNA Cancer Immunotherapy iNeST and FixVac Portfolio Development Focus 15 Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron. Autogene cevumeran1 BNT113 BNT116 Adjuvant Adjuvant 1L Multiple settings CRC Phase 2 PDAC Phase 2 HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2
Slide 16: Multiple Milestones Achieved so Far in 2026
Multiple Milestones Achieved so Far in 2026 16 Program Trial Readout Phase Indication Status Context Late-Stage Trial Readouts Trastuzumab pamirtecan3 Single arm Phase 2 2L+ HER2-expressing endometrial cancer Achieved Phase 35 primary analysis Chemo naïve HR+ HER2-low breast cancer Achieved in Q3 Me
Slide 17: Financial Performance
Financial Performance Ramón Zapata, Chief Financial Officer 4 17
Slide 18: Third Quarter 2026 Financial Results
In € millions except per share data1 Q3 2026 Q3 2025 IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 Revenues 1,289 1,289 1,519 1,519 Cost of sales (103) (92) (148) (148) Research and development expenses (748) (579) (565) (479) Sales, marketing, general and administrative expenses (17
Slide 19: Q3 Year-to-Date 2026 Financial Results at a Glance
Q3 Year-to-Date 2026 Financial Results at a Glance1 Continued Focus on R&D Priority Programs 19 Revenues € 1,513 MILLION vs. €1,963 million year-to-date 2025 Adjusted R&D Expenses² € 1,583 MILLION vs. €1,514 million year-to-date 2025 IFRS R&D Expenses: €1,856 million vs. €1,600 million year-to-date
Slide 20: Updated Full Year 2026 Financial Guidance
Updated Full Year 2026 Financial Guidance1 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based on non
Slide 21: Thank you
Thank you
Slide 22: Appendix
— Appendix BIONT=CrH
Slide 23: Reconciliation of IFRS to Adjusted Results – Q3 2026 & 2025
Reconciliation of IFRS to Adjusted Results – Q3 2026 & 2025 Financial Results In € millions except per share data1 Q3 2026 Q3 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 1,289 – 1,289 1,519 – 1,519 Cost of sales (103) 11 (92)
Slide 24: Reconciliation of IFRS to Adjusted Results – YTD 2026 & 2025
Reconciliation of IFRS to Adjusted Results – YTD 2026 & 2025 Financial Results In € millions except per share data1 Year-to-date 2026 Year-to-date 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 1,513 – 1,513 1,963 – 1,963 Cost of
Slide 25: BioNTech's Oncology Pipeline
BioNTech’s Oncology Pipeline 25 Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8. Trial ongoing in China only; 9. Trial is currently being conducted by or on behalf of BioNTech.
Slide 26: BioNTech's Infectious Diseases Pipeline
26 Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI). mRNAAntibody BioNTech’s Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 HSV BNT1644 Tube
Slide 27: Abbreviation Directory
Abbreviation Directory 27 n L nth line FY Fiscal year OS Overall survival AACR American Association for Cancer Research G7 markets Canada, France, Germany, Italy, Japan, GB, USA PDAC Pancreatic ductal adenocarcinoma ADC Antibody-drug conjugate GB Great Britain PD-(L)1 Programmed cell death protein (